Arix Bioscience plc announces the unaudited estimated Net Asset Value (NAV) of the Company for July 2023. The breakdown of the NAV includes a total NAV of £69 million, with £65.7 million in the listed portfolio, £100 million in the unlisted portfolio, £2.8 million in cash, and £237.5 million in other interests. The NAV per share is £1.84. Arix Bioscience is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies.